Ποια είναι η τιμή για ObsEva S.A. (OBSN)

Η τιμή για ObsEva S.A. (OBSN) είναι $0.00156067

Ποια είναι η κεφαλαιοποίηση αγοράς για ObsEva S.A. (OBSN)

Η κεφαλαιοποίηση αγοράς για ObsEva S.A. (OBSN) είναι $182.87K

ObsEva S.A. (OBSN) Ιστορικό Τιμών

ObsEva S.A. is a biopharmaceutical company focused on developing and commercializing groundbreaking therapies for women facing challenges in reproductive health and pregnancy. Its product pipeline includes Linzagolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist currently in Phase III clinical trials. Linzagolix is being evaluated for its efficacy in treating pain associated with endometriosis and heavy menstrual bleeding linked to uterine fibroids in pre-menopausal women. The firm is also progressing with Ebopiprant, an oral and selective prostaglandin F2a (PGF2a) receptor antagonist, which is in Phase II clinical trials as a once-daily treatment for preterm labor occurring between 24 and 34 weeks of gestational age. Additionally, ObsEva is developing Nolasiban, an oral oxytocin receptor antagonist in Phase I clinical trials, aimed at enhancing clinical pregnancy and live birth rates for women undergoing in vitro fertilization. ObsEva S.A. was founded in 2012 and maintains its headquarters in Geneva, Switzerland.

Έτος	Απόδοση
2024	-92.05%
2023	-71.26%
2022	-92.71%
2021	1.17%
2020	-41.38%
2019	-73.99%
2018	0.00%

Έτος

Απόδοση

2024

-92.05%

2023

-71.26%

2022

-92.71%

2021

1.17%

2020

-41.38%

2019

-73.99%

2018

0.00%

Εταιρεία	Τιμή μετοχής	Μεταβολή 1Έτ%	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	$517.18	32.51%	US
Argenx SE ARGX.US	$857.76	31.47%	NL
Lonza Group AG LONN.SW	$744.96	9.07%	CH
Samsung Biologics Co.,Ltd. 207940.KS	$1.08K	-5.43%	KR
UCB S.A. UCB.BR	$259.89	14.81%	BE

Εταιρεία

Τιμή μετοχής

Μεταβολή 1Έτ%

Χώρα